Glynium Respules contain Glycopyrrolate 25 mcg per 2 ml, a potent anticholinergic agent primarily used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Glycopyrrolate acts by selectively blocking muscarinic receptors in the airway smooth muscle, resulting in bronchodilation and reduced mucus secretion. Administered via nebulization, Glynium Respules provide rapid relief from bronchospasm and improve airflow obstruction, thereby enhancing respiratory function and patient comfort. This medication is particularly beneficial for patients who require maintenance therapy to control symptoms of bronchoconstriction and reduce exacerbations. The 2 ml respules are designed for use with standard nebulizer devices, ensuring efficient delivery of the drug to the lower respiratory tract. Glycopyrrolate exhibits a prolonged duration of action, allowing for twice-daily dosing in most cases. It is generally well tolerated; however, patients should be monitored for potential anticholinergic side effects such as dry mouth, urinary retention, and tachycardia. Glynium Respules should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. It is contraindicated in patients with hypersensitivity to glycopyrrolate or other anticholinergic agents.